Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is gaining attention as a biotech stock supported by robust commercial results and pipeline advancements. The company posted a total revenue of $203.1 ...

If not, you can flip the stock at any time for a profit. Investors have seriously recognized biotechnology as a distinct market sector since 1993. The Biotechnology Innovation Organization (BIO ...

Argus has a "buy" rating and $400 price target for UTHR stock, which closed at $362.33 on Jan. 7. Bio-Techne develops, manufactures and sells biotechnology reagents and instruments for the ...

With a potential FDA approval on the horizon and promising pipeline progress, Precigen stands out as a hot biotech stock worth watching. Overall, PGEN ranks 4th on our list of hot biotech stocks ...

The improved sales of Nerlynx have been the primary reason for the stock’s increase in the past six months. Puma Biotechnology in-licensed the global development and commercialization rights to ...

This fund holds a portfolio of 75-125 biotechnology stocks ... bearish on Moderna's coronavirus vaccine and underweighted the stock in 2020 and 2021, which hurt the fund's relative performance ...